Manzo Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNZO research report →
Companywww.lactofreedom.com
Manzo Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the research, development, and testing of patented and non-patented solutions and remedies. The company is involved in developing Lacto-Freedom, a patented probiotic, which aids in the digestion of lactose containing foods primarily for people with lactose intolerance; and a natural remedy for colic in babies.
- CEO
- Kenneth Manzo
- IPO
- 1998
- Employees
- 12
- HQ
- Milford, PA, US
Price Chart
Valuation
- Market Cap
- $115.95K
- P/E
- -3.20
- P/S
- 57.57
- P/B
- 0.64
- EV/EBITDA
- 116.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.37%
- Op Margin
- 39.37%
- Net Margin
- -1799.60%
- ROE
- -544.53%
- ROIC
- 0.41%
Growth & Income
- Revenue
- $2.01K · 267.52%
- Net Income
- $-36,244 · 96.34%
- EPS
- $-0.00 · 98.92%
- Op Income
- $793
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -44.70
- Avg Volume
- 41.38K
Get TickerSpark's AI analysis on MNZO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MNZO Coverage
We haven't published any research on MNZO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MNZO Report →